HOCHDORF Holding AG - M&A Activity 2016

News Details

Ad-hoc | 20 December 2016 07:00

HOCHDORF Holding AG: Shareholding brings HOCHDORF closer to the end user

HOCHDORF Holding AG / Key word(s): Investment

20-Dec-2016 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 KR

HOCHDORF Group Press Release: Shareholding brings HOCHDORF closer to the end user

Closing of the majority shareholding for Pharmalys

Hochdorf, 20 December 2016 – With all pre-conditions met, the closing for the majority holding in Pharmalys Laboratories SA and in the jointly-founded Pharmalys Africa Sarl has been completed. HOCHDORF currently has a 49% holding in Pharmalys Tunisia SA. This means that the integration of these companies into the HOCHDORF Group can be completed by the end of 2016.

With all conditions met, the closing of the HOCHDORF Group’s shareholdings in the Pharmalys Group companies has been completed today (Monday). This means that HOCHDORF assumes a 51% majority holding in Pharmalys Laboratories SA and in the jointly-founded Pharmalys Africa Sarl effective at the end of 2016. Only 49% of the shares are being acquired in Pharmalys Tunisia SA in a first step. The expectation is that the shareholding will likewise increase to 51% once the takeover procedure has been approved.

Forward integration strategy

The holding in Pharmalys is an important milestone towards meeting the Group’s strategic objectives for 2020. By then HOCHDORF Group aims to develop into a globally active, profitable niche-market company with premium products. “HOCHDORF aims to move closer towards the end user and this majority holding in Pharmalys is an important step in this direction,” says Thomas Eisenring, CEO of the HOCHDORF Group. Pharmalys is active in over 40 countries in the Middle East, Africa and Asia. HOCHDORF has been producing infant formula for Pharmalys since 2008.

On 29 November 2016, HOCHDORF Holding Ltd shareholders voted for a capital increase that was necessary for the majority shareholding as well as an increase to the transferability restrictions from 5% to 15%. Additional details relating to the Pharmalys transaction are available on the HOCHDORF Group website: www.hochdorf.com .

Contact:

Christoph Hug, Head of Corporate Communications, HOCHDORF Group.

Tel: +41 (0)41 914 65 62 / +41 (0)79 859 19 23, [email protected]

Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=MNEWDVEQKD

Document title: Closing HOCHDORF – Pharmalys

End of ad hoc announcement

Information and Explanation of the Issuer to this News:

In 2015 the HOCHDORF Group, which is headquartered in Hochdorf, generated a consolidated gross sales revenue of CHF 551.2 million. It is one of the leading foodstuff companies in Switzerland, with more than 625 employees as at 31 December 2015. Made from such natural ingredients as milk, wheat germ, and oilseeds, HOCHDORF products have been contributing to the health and well-being of the young and old alike since 1895. Our customers include the food industry and wholesalers and retailers. Our products are sold in more than 90 countries. HOCHDORF stock is traded on the SIX Swiss Exchange in Zurich (ISIN CH0024666528).


Language:	English
Company:	HOCHDORF Holding AG
	Siedereistrasse 9
	6281 Hochdorf
	Switzerland
Phone:	+41 41 914 65 65
Fax:	+41 41 914 66 66
E-mail:	[email protected]
Internet:	www.hochdorf.com
ISIN:	CH0024666528
Listed:	SIX Swiss Exchange